Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

TNYA has been the subject of a number of other reports. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Chardan Capital lowered their target price on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $14.75.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $3.29 on Monday. Tenaya Therapeutics has a 12-month low of $1.61 and a 12-month high of $7.01. The firm has a fifty day moving average of $2.06 and a 200-day moving average of $2.84. The firm has a market capitalization of $260.63 million, a price-to-earnings ratio of -2.28 and a beta of 2.34.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. Research analysts expect that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. abrdn plc bought a new position in shares of Tenaya Therapeutics in the third quarter valued at $1,063,000. Vanguard Group Inc. increased its stake in shares of Tenaya Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock worth $14,973,000 after purchasing an additional 403,472 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Tenaya Therapeutics by 27.7% in the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock valued at $317,000 after purchasing an additional 22,146 shares during the period. Dimensional Fund Advisors LP lifted its stake in Tenaya Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock valued at $316,000 after purchasing an additional 30,446 shares during the last quarter. Finally, Algert Global LLC bought a new position in Tenaya Therapeutics during the second quarter worth about $74,000. 90.54% of the stock is owned by institutional investors and hedge funds.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.